Mesa Laboratories Reports 2.4% Revenue Increase and 40% Net Income Growth in Q1 FY 2026

Mesa Laboratories, Inc. reported a modest increase in revenue for the first quarter of fiscal year 2026, with total revenues reaching $59.5 million, up 2.4% from $58.2 million in the same period last year. The company’s net income also saw a significant rise, increasing 40% to $4.7 million compared to $3.4 million in the prior year. This growth in profitability was reflected in earnings per share, which rose to $0.87 for basic shares and $0.85 for diluted shares, compared to $0.63 and $0.62, respectively, in the previous year.

The financial performance was influenced by several operational changes. The Sterilization and Disinfection Control division experienced a notable revenue increase of 10.7%, driven by strong sales volumes and improved order fulfillment. However, the Biopharmaceutical Development and Clinical Genomics divisions faced challenges, with revenues declining by 4.3% and 9.7%, respectively, due to customer purchasing delays amid macroeconomic uncertainties and tariff conditions. Overall, gross profit as a percentage of revenues decreased to 62.0%, down from 64.0% in the prior year, primarily due to increased costs and a shift in product mix.

In terms of strategic developments, Mesa Laboratories has continued to focus on enhancing its operational efficiency and expanding its market presence. The company has been actively pursuing acquisitions to broaden its product offerings and customer base. As of June 30, 2025, Mesa's total assets increased slightly to $435.7 million from $433.3 million, with goodwill rising to $188.1 million, reflecting ongoing investments in growth. The company also reported a decrease in cash and cash equivalents, which fell to $21.3 million from $27.3 million, indicating a shift in liquidity management.

Operationally, Mesa Laboratories reported a decrease in customer engagement metrics, with total cash provided by operating activities dropping to $1.9 million from $10.7 million in the previous year. This decline was attributed to lower gross margins and increased cash payments for accrued bonuses and commissions. The company’s workforce remained stable, with no significant changes in employee headcount reported during the quarter.

Looking ahead, Mesa Laboratories anticipates continued challenges from global economic conditions, including inflationary pressures and tariff impacts. The company plans to implement price increases and cost-saving measures to mitigate these effects. Management remains optimistic about future growth, particularly in the Sterilization and Disinfection Control and Calibration Solutions divisions, while acknowledging the need to navigate the complexities of the current market environment.